Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 18/20 | 0.71 |
| ▸ | MAOB | P27338 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890267 | 0.90 | SMN1; SMN2 (0.61) | AOC3MAOBSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL3936758 | 0.87 | AOC3 (0.74) | AOC3MAOBSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL973780 | 0.86 | AOC3 (0.56) | AOC3MAOBSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL12947692 | 0.86 | AOC3 (0.53) | AOC3MAOBSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL4882312 | 0.85 | AOC3 (0.55) | AOC3MAOBSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL4872931 | 0.85 | AOC3 (0.71) | AOC3MAOBSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL972537 | 0.84 | AOC3 (0.78) | AOC3MAOBSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL975119 | 0.84 | AOC3 (0.78) | AOC3MAOBSMN1; SMN2KMT2A | |
| SCHEMBL971466 | 0.84 | AOC3 (0.78) | AOC3MAOBSMN1; SMN2KMT2A | |
| SCHEMBL3405947 | 0.83 | AOC3 (0.76) | AOC3MAOBSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786792-B1 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | ASTELLAS PHARMA INC (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1786792-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | Astellas Pharma Inc. (JP) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006011631-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | VCAM1, VAPB, VAPA | AOC3 386/4885MAOB 3666/4885SMN1; SMN2 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.